Is Melanotan 2 FDA approved?

No. Melanotan II has never been approved by FDA for any indication, and Drugs@FDA holds no application for it: queries by generic name, by active-ingredient name, and by unfielded full-text search all returned NOT_FOUND on 2 August 2026, as did the FDA drug label endpoint. FDA has stated the point directly in a final Federal Register order, describing Melanotan II as 'an unapproved new drug'. The confusion usually comes from a different molecule: afamelanotide, marketed as SCENESSE, is an FDA-approved melanocortin 1 receptor agonist under NDA 210797 — but it is a different and larger molecule, described on its own label as 'a synthetic peptide containing 13 amino acids', and that label indicates it 'to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)', a rare inherited disorder. An approval belonging to another molecule for another purpose is not an approval for Melanotan II.

Is Melanotan 2 legal in the US in 2026?

No, not for sale for human use, and the answer here is unusually well documented. FDA's position is that Melanotan II is an unapproved new drug that cannot be introduced into interstate commerce without an approved application, and that position has been tested to judgment: FDA's final order at 81 FR 79501, effective 14 November 2016, permanently debars Edward Manookian, owner of Melanocorp, Inc., after the U.S. District Court for the Middle District of Tennessee entered judgment against him on two counts of conspiracy under 18 U.S.C. 371 for conduct relating to the sale of Melanotan II as an injectable tanning product. FDA also told that seller in writing that unapproved new drugs do not qualify for export. Separately, Melanotan II is absent from FDA's 503A bulk drug substances list, so it may not lawfully be used in pharmacy compounding either. Being widely available for sale online is not the same question as being lawful to sell.

Does Melanotan 2 cause melanoma?

Not established — and the honest answer is that the study which would settle it has never been done. What exists is a case literature, and FDA points at it: on its own safety-risks page FDA writes that 'Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism' for Melanotan II. Dermatologists have published cases of melanoma and melanoma in situ in melanotan users, together with reports of eruptive and dysplastic naevi and darkening of pre-existing moles after injection. Case reports establish association and sequence, not causation, and most users of injectable melanotropic peptides also use ultraviolet exposure, which confounds any single case. What the literature does bear on is the specific claim these products are sold with — that an injected tan is a safer tan — and it does not support it.

Are there any human clinical trials of Melanotan 2?

Yes, but only three, all small, and all finished a quarter-century ago. Melanotan II was administered to human subjects by subcutaneous injection in a pilot phase-I study in 3 normal male volunteers reported by Dorr and colleagues in Life Sciences in 1996, and in two double-blind, placebo-controlled crossover studies at the University of Arizona reported by Wessells and colleagues in The Journal of Urology in 1998 and in Urology in 2000, each enrolling 10 men with erectile dysfunction. That is 23 subjects in total, and nothing has been added since. Note what the controlled studies measured: erections, not tanning. In the 1998 study the investigators reported a mean duration of penile tip rigidity greater than 80% of 38.0 minutes with Melanotan-II versus 3.0 minutes with placebo. The tanning effect the compound is actually sold for was reported in the 1996 pilot, in which increased pigmentation was observed in 2 of the 3 volunteers — an open study in three men. One further trial is registered on ClinicalTrials.gov, NCT07437560, but its own summary opens 'This example interventional study record describes …', it reports itself as not an FDA-regulated drug study, and it has posted no results.

Can I get Melanotan 2 from a compounding pharmacy?

Not lawfully. Melanotan II appears in none of the three categories of FDA's 503A bulk drug substances list, updated 14 May 2026 and text-extracted directly on 2 August 2026, which returns zero hits for 'melanotan' in any form. A bulk drug substance that is neither the subject of a USP monograph nor a component of an FDA-approved drug product must appear on that list to be used in compounding under section 503A, and Melanotan II is not an ingredient of any approved product. FDA lists it instead in a table headed 'Bulk drug substances nominated but withdrawn', whose own header explains that these substances were 'previously in category 2 of the interim policies' and 'were withdrawn by the nominators'. A withdrawal by the party that nominated the substance is not a decision by FDA in the substance's favour, and it did not move Melanotan II onto the list.

Did the FDA advisory committee that backed BPC-157 in July 2026 also cover Melanotan 2?

No. Melanotan II was not on the agenda of the Pharmacy Compounding Advisory Committee meeting held on 23-24 July 2026 and received no committee review, no discussion and no vote. The agenda, text-extracted on 2 August 2026, returns zero hits for 'melanotan'; the substances heard were the BPC-157-related, KPV-related, TB-500-related, MOTS-c-related, semax-related, epitalon-related and emideltide-related bulk drug substances, and no others. The overlap that causes the confusion is real but narrow: Melanotan II sits in the same FDA table of substances nominated but withdrawn as those seven. Sharing a table is not sharing a proceeding. Nothing that happened at that meeting applies to Melanotan II, and for the six substances the committee did recommend, the recommendation was non-binding and did not by itself change the 503A bulks list.

What are the documented side effects of Melanotan 2?

FDA names four in published case reports for Melanotan II: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. Each is traceable to peer-reviewed case literature. Clinicians reporting in Clinical Toxicology in 2012 described a man who developed systemic toxicity with sympathomimetic excess, rhabdomyolysis and renal dysfunction after injecting Melanotan II bought over the internet, requiring intensive-care admission — and the injected material was analysed by mass spectrometry and confirmed to be Melanotan II, which rules out the usual explanation that the vial contained something else. Urologists reporting in BMJ Case Reports in 2019 described acute low-flow priapism after injection, treated with cavernosal aspiration and irrigation, in a patient who had not recovered erectile function at four-week follow-up. In the compound's own supervised trials, investigators reported nausea, stretching and yawning more often with Melanotan II than with placebo, with severe nausea after 4 of 19 injections in the 2000 study. FDA separately states that compounded drugs containing Melanotan II may pose a risk for immunogenicity for certain routes of administration.

Melanotan II

Also sold as: Melanotan 2, Melanotan-II, MT-II, MT2, MII, Melanotan II acetate, the Barbie drug

Melanotan II is not an FDA-approved drug for any indication and never has been — Drugs@FDA returns no application for melanotan under any name — and FDA has stated in a final Federal Register order, 81 FR 79501, that Melanotan II is 'an unapproved new drug', an order permanently debarring the owner of a company that advertised it as an injectable tanning product following two federal felony conspiracy convictions. Melanotan II is also absent from FDA's 503A bulk drug substances list, so it may not lawfully be used in pharmacy compounding under section 503A; FDA lists it instead among bulk drug substances nominated but withdrawn, where FDA writes that 'Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.'

Which molecule this is. A synthetic cyclic analogue of alpha-melanocyte stimulating hormone (alpha-MSH). Dorr et al. 1996 give its structure as the lactam-bridged heptapeptide Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2. TWO SEPARATIONS MATTER AND BOTH ARE ROUTINELY COLLAPSED. First, Melanotan II is not afamelanotide: afamelanotide is a thirteen-amino-acid peptide (Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 per the SCENESSE label), it is FDA-approved under NDA 210797, and it is a different molecule under a different application. Sellers calling Melanotan II 'Melanotan 1's successor' are trading on that approval. Second, Melanotan II is not bremelanotide: the Melanotan II structure above terminates in a C-terminal amide, while the VYLEESI label gives bremelanotide as Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH), the free acid. We state the structural difference because both structures are in primary documents and can be compared. We do NOT assert the widely repeated claim that bremelanotide is a metabolite or derivative of Melanotan II — no primary document on this record says so, and the PT-141 record declines the same claim for the same reason.

FDA status

Not FDA-approved

FDA has not approved this and it is not in active development toward approval. That says nothing about whether it is being sold — most substances in this category are.

Not approved by FDA for any indication, and never has been — Drugs@FDA returns no application for melanotan under a generic name, an active-ingredient name, or a full-text search (see fdaFindings). NOT INVESTIGATIONAL, and the distinction is the whole of the difference between this record and a drug in development. The vocabulary here requires active development by an identifiable sponsor with registered trials. Exactly one trial of Melanotan II is registered anywhere — NCT07437560 — and its own brief summary opens 'This example interventional study record describes …'. A record that identifies itself as an example is not a development programme. The genuine human studies on this record are from the 1990s and nothing followed them; a programme that stopped is not a programme that is running. Note also what 'not approved' does not settle. It says nothing about whether Melanotan II is sold — it is sold widely — and it is not the whole of the legal exposure either. FDA's position, litigated to a federal conviction, is that selling it as an unapproved new drug violated the FD&C Act, and FDA told the seller in writing that unapproved new drugs do not qualify for export either.

Edward Manookian (Also Known as Ed Manning): Debarment Order, 81 FR 79501 (Docket No. FDA-2015-N-4169) — Federal Register (U.S. Food and Drug Administration), 14 November 2016

“Mr. Manookian's company advertised MII, an unapproved new drug, as an injectable tanning product through an internet Web site.”

Checked against the source on 2 August 2026.

503A compounding

Withdrawn from nomination

The nominator withdrew the nomination. This is not a legalisation event — the substance is not on the 503A bulks list and remains non-compoundable.

The nominator withdrew; FDA did not clear anything. Melanotan II is absent from all three categories of the 503A bulk drug substances list (updated 2026-05-14), which was fetched with a browser user-agent and text-extracted on 2026-08-02 — a search of the full extracted text returns zero hits for 'melanotan' in any form. A bulk drug substance that is neither the subject of a USP monograph nor a component of an approved drug product must appear on that list to be used in 503A compounding. Melanotan II does not appear on it, so it may not lawfully be used in 503A compounding. AND THE WITHDRAWAL DID NOT REMOVE FDA'S CONCERNS — FDA published them on the same page, under the same table, and has never taken them down. See fdaFindings for the verbatim text.

Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA, 22 April 2026

“Bulk drug substances nominated but withdrawn — This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.”

Checked against the source on 2 August 2026.

Evidence

Promising but unproven

There is human data, but efficacy is not established. This includes programmes that were tested and failed.

ADMINISTRATION CHECK RUN AND PASSED, and it is the reason this record does not read like the rest of the library. Three studies were opened individually on 2026-08-02 (PubMed abstracts, not full texts — we say which, because the distinction is exactly the kind we hold others to). All three are interventional and all three administered Melanotan II to human subjects by subcutaneous injection: Dorr et al. 1996, a single-blind, placebo-controlled pilot phase-I study in 3 normal male volunteers; Wessells et al. 1998, a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction; and Wessells et al. 2000, a double-blind, placebo-controlled crossover study in 10 men with organic risk factors. None measures an endogenous peptide as a biomarker — the failure mode that reduces MOTS-c's and TB-500's apparent human counts to zero. THE TIER LABEL IS THE FLOOR, NOT THE FINDING. Read three things against it. (1) SCALE. The entire human record for this compound is 23 subjects across three studies, all at one institution, all published between 1996 and 2000. Nothing has been added in the quarter-century since, and 'promising-but-unproven' is the tier the vocabulary reserves for programmes with a human signal that were tested and never established, explicitly including ones that stopped. This one stopped. (2) THE ENDPOINT MISMATCH, which is the part that matters commercially. The two placebo-controlled crossover studies measured ERECTIONS, not tanning: Wessells 1998 reported a mean duration of tip rigidity greater than 80% of 38.0 minutes with Melanotan-II versus 3.0 with placebo (p=0.0045), and Wessells 2000 reported 45.3 minutes versus 1.9 (p=0.047). The tanning claim — the use Melanotan II is overwhelmingly sold for — rests on Dorr 1996, in which increased facial, upper-body and buttock pigmentation was reported in 2 of the 3 volunteers. That is the whole of the controlled human evidence for the effect people buy it for: an open pilot in three men. (3) TOLERABILITY WAS A FINDING, NOT A FOOTNOTE. Wessells 2000 reported that 4 of 19 Melanotan II injections were associated with severe nausea, in a supervised trial setting. None of this establishes efficacy for anything, and none of it was generated under the conditions people now buy the compound in.

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study (Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N; The Journal of Urology 1998;160(2):389-93) — PubMed, 1 August 1998

“Ten men with erectile dysfunction of no known organic cause were entered in a double-blind, placebo controlled crossover study in which the erectogenic properties of Melanotan-II and a vehicle placebo were compared using real-time RigiScan monitoring.”

Checked against the source on 2 August 2026.

What FDA found

FDA’s own words. These are the most citable thing on this site, and the least likely to appear anywhere funded by someone selling the compound.

FDA states, in a final Federal Register order, that Melanotan II was advertised as an injectable tanning product and that it is an unapproved new drug. The order permanently debars the seller's owner following two federal felony conspiracy convictions.
This is the single most citable document on the record and it is not a press release, a prosecution announcement or a news story — it is FDA's own final order, published at 81 FR 79501 on 14 November 2016, effective the same day, under Docket No. FDA-2015-N-4169. The order recites the underlying judgment: on 28 August 2015 the U.S. District Court for the Middle District of Tennessee entered judgment against Edward Manookian, President and owner of Melanocorp, Inc., for two counts of conspiracy to commit an offense against the United States in violation of 18 U.S.C. 371. FDA's characterisation of the conduct is quoted here in full because it is the agency's, not ours: 'Mr. Manookian knowingly sold unapproved drugs and put patients at risk.' Two details are worth keeping. First, FDA sent a warning letter on or about 30 August 2007, the company told FDA it had stopped U.S. sales, and shipments continued anyway — the conviction is for the conspiracy to defraud that followed, not for the original sales. Second, the order records that the Melanocorp website 'also advertised MII as being 100 percent U.S. made, whereas in fact some of the MII sold by Melanocorp was manufactured in and imported from China.' A provenance claim on a seller's website is a marketing statement, and in the one case where a court examined one it was false.
Edward Manookian (Also Known as Ed Manning): Debarment Order, 81 FR 79501 (Docket No. FDA-2015-N-4169) — Federal Register (U.S. Food and Drug Administration), 14 November 2016
“Melanotan II (MII) was a peptide, or series of amino acids, that was marketed, sold, and shipped by Melanocorp to customers in the United States and abroad. Mr. Manookian's company advertised MII, an unapproved new drug, as an injectable tanning product through an internet Web site.”
Checked against the source on 2 August 2026.
FDA published its own safety concerns for Melanotan II, in FDA's words: a risk of immunogenicity for certain routes of administration, and published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
THIS ENTRY IS THE OUTLIER OF THE PAGE IT SITS ON, and the comparison is checkable: both tables were extracted on 2026-08-02, and Melanotan II is the ONLY substance anywhere on that page for which FDA writes the words melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome or priapism. Its sixteen table-mates read the other way — KPV and MOTS-c get 'FDA has not identified any human exposure data', BPC-157 gets 'no, or only limited, safety-related information'. Melanotan II is not on this list because FDA knows nothing about it. It is on the list partly because of what has been reported. The withdrawal changes none of this. FDA left the entry standing after the nomination was withdrawn, which forecloses the reading — the one this site exists to correct — that leaving Category 2 means the concerns were resolved.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA, 22 April 2026
“Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”
Checked against the source on 2 August 2026.
Drugs@FDA contains no application for melanotan under any name. Queried on 2026-08-02 by generic name, by active-ingredient name, and by unfielded full-text search, all returning NOT_FOUND; the drug label endpoint returns NOT_FOUND as well.
Recorded with the queries stated because a NOT_FOUND is only as good as the field it was asked of. openFDA's `openfda` blocks are sometimes empty, and this library has already shipped one false 'not in Drugs@FDA' claim that was an artifact of querying a single field. Both fields were tried, plus a bare full-text search across the whole database, plus the label endpoint. The same query shapes return NDA210797 for afamelanotide on the first attempt, so the absence is the database's, not the query's. openFDA reported meta.last_updated 2026-07-31 at the time of the check. Re-run the URL to re-verify; it is a live query, not a PDF.
Drugs@FDA — approved drug products database, queried for melanotan (openFDA) — FDA, 2 August 2026
“{ "error": { "code": "NOT_FOUND", "message": "No matches found!" } }”
Checked against the source on 2 August 2026.
Melanotan II appears nowhere in Categories 1, 2 or 3 of FDA's 503A bulk drug substances list, updated 2026-05-14.
Verified by fetching the PDF with a browser user-agent and extracting all seven pages locally on 2026-08-02: a case-insensitive search of the full text returns zero hits for 'melanotan'. Read this absence the way BPC-157's is read, not the way bremelanotide's is: Melanotan II is not the active ingredient of any approved drug product, so the 503A nomination pathway WAS the relevant one for it, it was on that pathway, and it left by withdrawal. Absence from the list means it may not lawfully be used in 503A compounding.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.
Melanotan II was not among the seven bulk drug substances the Pharmacy Compounding Advisory Committee considered at its meeting of 23-24 July 2026, and received no committee review or recommendation.
Stated because the inference readers will make is wrong in a specific and predictable way. Melanotan II sits in the same 'nominated but withdrawn' table as BPC-157, TB-500, KPV, MOTS-c, semax, epitalon and emideltide, six of which the committee voted to recommend for the 503A list in July 2026. The agenda was fetched and text-extracted on 2026-08-02 and returns zero hits for 'melanotan': the substances heard were BPC-157-related, KPV-related, TB-500-related, MOTS-c-related, semax-related, epitalon-related and emideltide-related bulk drug substances, and no others. So the 'FDA panel backs the peptides' coverage does not reach Melanotan II at all — there was no vote about it, favourable or otherwise. Separately, and for the six it does reach, a committee recommendation is non-binding and did not change the list.
Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — Agenda — FDA, 23 July 2026Checked against the source on 2 August 2026.
FDA told the seller in writing that unapproved new drugs do not qualify for export, after the seller took the position that it could lawfully export Melanotan II regardless of that status.
A failed legal theory, recorded as a failed one. The export argument sits beside research-use-only labelling in the same family of workarounds this market relies on: an assertion about paperwork offered against a status that turns on the product itself. FDA rejected it in writing at the time, the order records that shipments continued anyway, and the sequence ended in a federal conviction and permanent debarment.
Edward Manookian (Also Known as Ed Manning): Debarment Order, 81 FR 79501 (Docket No. FDA-2015-N-4169) — Federal Register (U.S. Food and Drug Administration), 14 November 2016
“On or about December 28, 2007, FDA sent a letter to Mr. Manookian's attorney which reiterated that unapproved new drugs do not qualify for export.”
Checked against the source on 2 August 2026.
The only registered clinical trial of Melanotan II anywhere describes itself in its own brief summary as an example study record, states that it is not an FDA-regulated drug study, and has posted no results.
Retrieved from the ClinicalTrials.gov v2 API on 2026-08-02 and read field by field, because this is the registration a vendor will cite as proof that Melanotan II is 'in Phase 2 trials'. On its face it is impressive: randomized, quadruple-masked, parallel-group, placebo-controlled, 60 estimated participants. Every contamination marker this library has catalogued is also present. Its own summary calls it an example record. Its oversight module reports isFdaRegulatedDrug: false. Its actual start date is 2026-02-02 and it has been RECRUITING since, with no results and an estimated — not actual — enrolment. Its lead sponsor, an industry entity named Hudson Biotech, lists contacts at a beijing-biotech.com domain against a hospital site in Shenzhen. Registration is self-reported and nobody vets it before it appears. This is not evidence, and it is not a development programme.
NCT07437560 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II … in Adults With Stable Nonsegmental Vitiligo — ClinicalTrials.gov, 27 February 2026
“This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.”
Checked against the source on 2 August 2026.

Documented safety signals

Clinicians reported a case of systemic toxicity with sympathomimetic excess, rhabdomyolysis and renal dysfunction after subcutaneous self-injection of Melanotan II bought over the internet, requiring intensive-care admission.
The detail that makes this case unusually hard to dismiss is analytical, not clinical. The authors report that the injected substance 'was analyzed via mass spectrometry and was confirmed to be Melanotan II when compared with an industry purchased standard sample'. The standard defence for a grey-market adverse event — that the vial contained something else — was tested here and did not hold. The reported course was tachycardia, mydriasis, diaphoresis and diffuse muscle tremors on presentation, a creatine phosphokinase that rose roughly tenfold over the following 12 hours, and discharge from the ICU after 3 days. A single case report establishes a possible association, not a rate.
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Nelson ME, Bryant SM, Aks SE; Clinical Toxicology 2012;50(10):1169-73) — PubMed, 1 December 2012
“Melanotan II use resulted in systemic toxicity including apparent sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction.”
Checked against the source on 2 August 2026.
Urologists reported a case of acute low-flow priapism after subcutaneous abdominal injection of melanotan, managed with cavernosal aspiration, irrigation and intracavernosal phenylephrine; the patient had not recovered erectile function at four-week follow-up.
Read this against the evidence section rather than apart from it. The only placebo-controlled human studies of Melanotan II were erection studies, and the erectogenic effect they measured is the same pharmacology that produces this. The authors' own framing is that any 'future therapeutic application of these agents will need to take this potential life altering complication into consideration'. Low-flow priapism is a time-critical urological emergency; the mechanism working harder than intended is not a different event from the mechanism working.
Melanotan-induced priapism: a hard-earned tan (Dreyer BA, Amer T, Fraser M; BMJ Case Reports 2019;12(2):e227644) — PubMed, 21 February 2019
“The patient avoided requiring surgical shunting but had not yet recovered erectile function at 4-week follow-up.”
Checked against the source on 2 August 2026.
Physicians reported a case of posterior reversible encephalopathy syndrome associated with melanotan in the Annals of Internal Medicine — one of the four serious adverse events FDA names for Melanotan II on its own safety-risks page.
Cited by title and journal only. The record is a brief correspondence item and its abstract is not indexed in PubMed, so nothing is quoted from it here and no clinical detail is asserted beyond what the title carries — which is the honest limit of what was actually opened. It is recorded because it is one of the published case reports FDA's safety text points at, and because posterior reversible encephalopathy syndrome is a neurological emergency that no one buying a tanning product is watching for.
Melanotan and the posterior reversible encephalopathy syndrome (Kaski D, Stafford N, Mehta A, Jenkins IH, Malhotra P; Annals of Internal Medicine 2013;158(9):707-8) — PubMed, 7 May 2013Checked against the source on 2 August 2026.
Dermatologists have reported melanoma and melanoma in situ arising in melanotan users, alongside a wider case literature on eruptive and dysplastic naevi and darkening of pre-existing naevi following melanotan injection.
STATE THE LIMIT PLAINLY: these are case reports, and case reports establish association and temporal sequence, not causation. Nobody has run the study that would settle it, and given the compound's legal status nobody will. Two things keep this on the record anyway. FDA itself lists melanoma first among the serious adverse events in published case reports for Melanotan II. And the confounding runs toward the compound rather than away from it — melanotan is used to tan, users typically also use ultraviolet exposure, and the case series repeatedly describe both together. A related 2011 report in the British Journal of Dermatology is titled 'Melanotan-associated melanoma'. The claim a seller makes — that an injected tan is the safer tan — is the one claim this literature bears on, and it does not support it.
Melanotan-associated melanoma in situ (Ong S, Bowling J; Australasian Journal of Dermatology 2012;53(4):301-2) — PubMed, 1 November 2012
“Injectable synthetic melanotropic peptides (often called melanotan) to enhance tanning are available over the Internet despite being unlicensed compounds with an unproven safety record. There have been reports of dysplastic naevi and melanoma associated with the use of melanotropic peptides. We report a case of melanotan-associated melanoma in situ.”
Checked against the source on 2 August 2026.
In the studies that administered it under supervision, investigators reported nausea, stretching and yawning more frequently with Melanotan II than with placebo, with severe nausea after 4 of 19 Melanotan II injections in the 2000 crossover study.
Recorded from the compound's own trials rather than from its critics. This is the tolerability profile observed in a screened, consented, clinically supervised population of ten men. Dorr et al. 1996 similarly reported mild nausea at most levels tested and grade II somnolence and fatigue in one of two volunteers at the highest level they reached. Whatever the human record of Melanotan II shows, an uneventful one is not it.
Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction (Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N; Urology 2000;56(4):641-6) — PubMed, 1 October 2000
“Nausea and stretching/yawning occurred more frequently with Melanotan II, and 4 of 19 injections were associated with severe nausea.”
Checked against the source on 2 August 2026.
A related melanocortin receptor agonist approved by FDA, bremelanotide, carries a labelled focal hyperpigmentation signal that FDA states was not confirmed to resolve in all patients after discontinuation.
READ THE SCOPE BEFORE READING THE SIGNAL. This is a finding about bremelanotide, not about Melanotan II, and it is recorded here as the closest thing that exists to a regulated safety dataset for a nonselective melanocortin agonist in humans — because for Melanotan II itself there is none. It cannot be transferred: different molecule, different application, different exposure. What makes it worth carrying is the direction of the inference. FDA's label attributes pigmentation to MC1R binding, the frequency rose sharply with more frequent use, and resolution after stopping was not confirmed in every patient. Melanotan II is bought specifically FOR pigmentation, which means it is bought by people seeking the effect that carried this signal, with no prescriber, no label and no follow-up.
VYLEESI (bremelanotide) injection — Highlights of Prescribing Information, original approval — FDA, 21 June 2019
“Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI.”
Checked against the source on 2 August 2026.

Questions people actually ask

Every answer cites the document behind it. Where the honest answer is “nobody knows”, that is the answer you will get.

Is Melanotan 2 FDA approved?: No. Melanotan II has never been approved by FDA for any indication, and Drugs@FDA holds no application for it: queries by generic name, by active-ingredient name, and by unfielded full-text search all returned NOT_FOUND on 2 August 2026, as did the FDA drug label endpoint. FDA has stated the point directly in a final Federal Register order, describing Melanotan II as 'an unapproved new drug'. The confusion usually comes from a different molecule: afamelanotide, marketed as SCENESSE, is an FDA-approved melanocortin 1 receptor agonist under NDA 210797 — but it is a different and larger molecule, described on its own label as 'a synthetic peptide containing 13 amino acids', and that label indicates it 'to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)', a rare inherited disorder. An approval belonging to another molecule for another purpose is not an approval for Melanotan II.
SCENESSE (afamelanotide) implant — current Structured Product Label, via the openFDA label API — FDA, 11 May 2026
“SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)”
Checked against the source on 2 August 2026.
Is Melanotan 2 legal in the US in 2026?: No, not for sale for human use, and the answer here is unusually well documented. FDA's position is that Melanotan II is an unapproved new drug that cannot be introduced into interstate commerce without an approved application, and that position has been tested to judgment: FDA's final order at 81 FR 79501, effective 14 November 2016, permanently debars Edward Manookian, owner of Melanocorp, Inc., after the U.S. District Court for the Middle District of Tennessee entered judgment against him on two counts of conspiracy under 18 U.S.C. 371 for conduct relating to the sale of Melanotan II as an injectable tanning product. FDA also told that seller in writing that unapproved new drugs do not qualify for export. Separately, Melanotan II is absent from FDA's 503A bulk drug substances list, so it may not lawfully be used in pharmacy compounding either. Being widely available for sale online is not the same question as being lawful to sell.
Edward Manookian (Also Known as Ed Manning): Debarment Order, 81 FR 79501 (Docket No. FDA-2015-N-4169) — Federal Register (U.S. Food and Drug Administration), 14 November 2016
“On August 28, 2015, the U.S. District Court for the Middle District of Tennessee entered judgment against Mr. Manookian for two counts of conspiracy to commit an offense against the United States, in violation of 18 U.S.C. 371.”
Checked against the source on 2 August 2026.
Does Melanotan 2 cause melanoma?: Not established — and the honest answer is that the study which would settle it has never been done. What exists is a case literature, and FDA points at it: on its own safety-risks page FDA writes that 'Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism' for Melanotan II. Dermatologists have published cases of melanoma and melanoma in situ in melanotan users, together with reports of eruptive and dysplastic naevi and darkening of pre-existing moles after injection. Case reports establish association and sequence, not causation, and most users of injectable melanotropic peptides also use ultraviolet exposure, which confounds any single case. What the literature does bear on is the specific claim these products are sold with — that an injected tan is a safer tan — and it does not support it.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — FDA, 22 April 2026
“Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”
Checked against the source on 2 August 2026.
Are there any human clinical trials of Melanotan 2?: Yes, but only three, all small, and all finished a quarter-century ago. Melanotan II was administered to human subjects by subcutaneous injection in a pilot phase-I study in 3 normal male volunteers reported by Dorr and colleagues in Life Sciences in 1996, and in two double-blind, placebo-controlled crossover studies at the University of Arizona reported by Wessells and colleagues in The Journal of Urology in 1998 and in Urology in 2000, each enrolling 10 men with erectile dysfunction. That is 23 subjects in total, and nothing has been added since. Note what the controlled studies measured: erections, not tanning. In the 1998 study the investigators reported a mean duration of penile tip rigidity greater than 80% of 38.0 minutes with Melanotan-II versus 3.0 minutes with placebo. The tanning effect the compound is actually sold for was reported in the 1996 pilot, in which increased pigmentation was observed in 2 of the 3 volunteers — an open study in three men. One further trial is registered on ClinicalTrials.gov, NCT07437560, but its own summary opens 'This example interventional study record describes …', it reports itself as not an FDA-regulated drug study, and it has posted no results.
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study (Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N; The Journal of Urology 1998;160(2):389-93) — PubMed, 1 August 1998
“Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p=0.0045).”
Checked against the source on 2 August 2026.
Can I get Melanotan 2 from a compounding pharmacy?: Not lawfully. Melanotan II appears in none of the three categories of FDA's 503A bulk drug substances list, updated 14 May 2026 and text-extracted directly on 2 August 2026, which returns zero hits for 'melanotan' in any form. A bulk drug substance that is neither the subject of a USP monograph nor a component of an FDA-approved drug product must appear on that list to be used in compounding under section 503A, and Melanotan II is not an ingredient of any approved product. FDA lists it instead in a table headed 'Bulk drug substances nominated but withdrawn', whose own header explains that these substances were 'previously in category 2 of the interim policies' and 'were withdrawn by the nominators'. A withdrawal by the party that nominated the substance is not a decision by FDA in the substance's favour, and it did not move Melanotan II onto the list.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.
Did the FDA advisory committee that backed BPC-157 in July 2026 also cover Melanotan 2?: No. Melanotan II was not on the agenda of the Pharmacy Compounding Advisory Committee meeting held on 23-24 July 2026 and received no committee review, no discussion and no vote. The agenda, text-extracted on 2 August 2026, returns zero hits for 'melanotan'; the substances heard were the BPC-157-related, KPV-related, TB-500-related, MOTS-c-related, semax-related, epitalon-related and emideltide-related bulk drug substances, and no others. The overlap that causes the confusion is real but narrow: Melanotan II sits in the same FDA table of substances nominated but withdrawn as those seven. Sharing a table is not sharing a proceeding. Nothing that happened at that meeting applies to Melanotan II, and for the six substances the committee did recommend, the recommendation was non-binding and did not by itself change the 503A bulks list.
Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 — Agenda — FDA, 23 July 2026Checked against the source on 2 August 2026.
What are the documented side effects of Melanotan 2?: FDA names four in published case reports for Melanotan II: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism. Each is traceable to peer-reviewed case literature. Clinicians reporting in Clinical Toxicology in 2012 described a man who developed systemic toxicity with sympathomimetic excess, rhabdomyolysis and renal dysfunction after injecting Melanotan II bought over the internet, requiring intensive-care admission — and the injected material was analysed by mass spectrometry and confirmed to be Melanotan II, which rules out the usual explanation that the vial contained something else. Urologists reporting in BMJ Case Reports in 2019 described acute low-flow priapism after injection, treated with cavernosal aspiration and irrigation, in a patient who had not recovered erectile function at four-week follow-up. In the compound's own supervised trials, investigators reported nausea, stretching and yawning more often with Melanotan II than with placebo, with severe nausea after 4 of 19 injections in the 2000 study. FDA separately states that compounded drugs containing Melanotan II may pose a risk for immunogenicity for certain routes of administration.
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (Nelson ME, Bryant SM, Aks SE; Clinical Toxicology 2012;50(10):1169-73) — PubMed, 1 December 2012
“The substance, which he injected, was analyzed via mass spectrometry and was confirmed to be Melanotan II when compared with an industry purchased standard sample.”
Checked against the source on 2 August 2026.